Plasma Clearance of Lovastatin Versus Chinese Red Yeast Rice in Healthy Volunteers

Zhaoping Li

Navindra P. Seeram
University of Rhode Island, nseeram@uri.edu

See next page for additional authors

Follow this and additional works at: https://digitalcommons.uri.edu/bps_facpubs

Terms of Use
All rights reserved under copyright.

Citation/Publisher Attribution
Available at: http://dx.doi.org/10.1089/acm.2005.11.1031
Plasma Clearance of Lovastatin Versus Chinese Red Yeast Rice in Healthy Volunteers

ZHAOPING LI, Ph.D., M.D., NAVINDRA P. SEERAM, Ph.D., RUPO LEE, M.Sc., GAIL THAMES, B.A., CHAYO MINUTTI, HE-JING WANG, M.P.H., M.D., and DAVID HEBER, Ph.D., M.D.

ABSTRACT

Objectives: It is now accepted that inhibition of cholesterol biosynthesis is effective in the primary and secondary prevention of heart disease. However, the perceived side-effects on muscle and liver reduce the general acceptance of statin drug therapy as well as compliance over the long term, which is necessary for prevention efforts to be successful. Chinese red yeast rice (CRYR) is a supplement containing lovastatin (monacolin K), eight other monacolins, pigments, tannins, and other phytochemicals. The authors previously reported on a double-blind placebo-controlled trial of CRYR supplement in 80 individuals demonstrating a significant decrease in cholesterol levels from 250 mg/dL to 210 mg/dL over 8 weeks independent of diet. The current study compared the pharmacokinetics of CRYR with lovastatin at the same bioeffective dose for lowering cholesterol.

Methods: Eleven (11) healthy volunteers were randomized to a crossover study taking 2400 mg CRYR or 20 mg of lovastatin.

Results: The Cmax and area under the curve (AUC) of lovastatin were 22.42 ng/mL, and 80.47 higher than CRYR (p = 0.001 and 0.002, respectively). The Cmax for lovastatin hydroxy-acid was 36.63 ng/mL higher than the Cmax of CRYR hydroxy-acid (p = 0.001). The AUC of lovastatin hydroxy-acid was 258.5 greater than that of CRYR (p = 0.001).

Conclusions: The results suggested that the effect of CRYR on the cholesterol concentration might be caused by the additive and/or synergistic effects of monacolin K with other monacolins and substances in CRYR. It may lead to the ultimate development of a botanical supplement based on CRYR.

INTRODUCTION

It is now accepted that inhibition of cholesterol biosynthesis is effective in the primary and secondary prevention of heart disease. Statin drugs, which are competitive inhibitors of HMG-CoA reductase, lower cholesterol levels and reduce the progression of atherosclerotic lesions while also stabilizing pre-existing atheromatous plaques. The perceived side-effects on muscle and liver reduce the general acceptance of statin drug therapy as well as compliance over the long term, which are necessary for prevention efforts to be successful.1 Surveys demonstrate that many Americans often turn to alternative herbal therapies for heart disease prevention rather than taking drugs,2,3 and view these as natural alternatives to drug therapy.

Chinese red yeast fermented on rice is a traditional food consumed throughout Asia. Its food value and medicinal value date back prior to its first recorded use in 800 AD.4,5 A dietary supplement of Chinese red yeast rice (CRYR) has been prepared that contains only a selected strain of Monascus purpureus Went yeast and white rice on which it was fermented. There are a number of constituents in the supplement including pigments, fatty acids, and polyketides (monacolins).6

The authors previously reported on a double-blinded placebo-controlled trial of this CRYR supplement in 80 individuals demonstrating a significant decrease in cholesterol
levels from 250 mg/dL to 210 mg/dL over 8 weeks independent of diet. The current study was designed to compare the pharmacokinetics of CRYR with lovastatin at the same bioeffective dose for lowering cholesterol to determine whether the body metabolizes complex mixtures of natural substances found in CRYR differently than lovastatin.

METHODS

Subjects

The study protocol was approved by the Ethics Committee of the University of California, Los Angeles and conducted at the General Clinical Research Unit (GCRC) of University of California, Los Angeles. Eleven (11) volunteers ages 25 to 45 year were recruited for the study. Written consent was obtained. All participants were in good health according to medical history, physical examination, electrocardiogram, and clinical laboratory measurements (serum chemistry, liver function tests, and hematology). Subjects were excluded if they were smokers, tobacco users, or taking any medication including over-the-counter medications within 14 days prior to the study.

Study design

This was an open label, randomized, crossover study with a 1-week washout period between two phases. The previous study had demonstrated that 2400 mg of CRYR is a relevant comparison dose to 20 mg of lovastatin for lowering blood cholesterol.\(^7\)

Kantola et al.\(^8\) reported that grapefruit increased the serum levels of lovastatin (C\(_{\text{max}}\)) approximately 12-fold and the area under the concentration-time curve (AUC) 15-fold by inhibiting CYP3A4-mediated first-pass metabolism in the small intestine. The present study uses the preceding method to increase the detectable levels of monacolins.

The subjects were given 200 mL of double-strength grapefruit juice (Minute Maid frozen concentrated grapefruit juice, 12 fluid ounces (355 mL), Coca-Cola Foods, Houston, TX) three times per day (at 7 AM, noon, and 8 PM) for 2 days. On day 3, the subjects reported to the GCRC at 7:30 AM after fasting from 11 PM the previous day. A caffeine-free standardized breakfast was served at 7:45 AM and either 20 mg of lovastatin or 2400 mg of Chinese red yeast rice was given with 200 mL of double-strength grapefruit juice at 8 AM. Standardized lunch and dinner were served at noon and 5 pm. The subjects returned to the GCRC the next morning to have their blood last drawn at 8 AM.

Sample collection

On the day of administration of lovastatin or CRYR, a forearm vein of each subject was cannulated with a plastic cannula and kept patent with a heparin flush. Blood samples were obtained at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours after taking lovastatin or taking CRYR. Whole blood was centrifuged immediately and plasma transferred to plastic tubes and frozen at \(-80^\circ\text{C}\) until assay.

Methodology for determination of monacolin K (lovastatin) and lovastatin hydroxy-acid in human plasma

Lovastatin 20–mg capsules were purchased from Merck & Co. Inc. (Whitehouse, NJ) CRYR dietary supplement 600-mg capsules were provided by Beijing WBL Peking University Biotech Co., Ltd, China.

HPLC-MS analyses were carried out on an LCQ Classic Finnigan LC-MS/MS system (ThermoFinnigan, San Jose, CA), equipped with a HP 1100 series HPLC system consisting of an autosampler and injector, quaternary pump, column...
heater, and diode array detector (DAD). Data handling was carried out using Xcalibur 1.2 software (ThermoFinnigan). Conditions for detection were as follows: Column, Symmetry C-18, 100 mm × 2.1 i.d., 3.5 µm, (Waters Corp., Milford, MA); Solvent A) 0.5% acetic acid/acetonitrile, B) 0.5% acetic acid/water; binary linear gradient system: 0–15 min: 50% A in B to 90% A in B; flow rate 0.2 mL/minute; injection volume 20 µL; column temperature 25°C. Mass spectrometer (MS) parameters: The MS (electrospray ionization; ESI) was operated in the negative mode for the first 11 minutes and then in the positive mode for the rest of the analytical run; scan range: 115–500 amu; scan rate: 1 scan/sec; cone voltage: 17 eV. Peak identities for lovastatin, lovastatin hydroxy-acid, and simvastatin were obtained by comparison of their LC-MS/MS ions with their standards.

Each C8 SPE cartridge was preconditioned with methanol (2 × 1 mL) and water (2 × 1 mL). Each plasma sample (400 µL) was loaded onto the cartridge and allowed to free-flow by gravity. Each cartridge was then eluted with consecutive aliquots of 1 mL water, 1 mL 5% formic acid, and then 1 mL of water. The cartridge was allowed to drip dry, left to stand for 1 minute, then eluted with 1 mL methanol: water (7:3 v/v) solution, and finally with 1 mL of acetonitrile. The combined acetonitrile eluates were evaporated to dryness in vacuo at low temperature, reconstituted in the HPLC mobile phase (100 µL), vortexed for 1 minute, and injected onto the LC column for LC-MS analyses.

Plasma calibration standards of lovastatin and its hydroxy-acid were prepared by spiking control human plasma with known concentrations of working solutions of the standards. Samples were processed according to the extraction procedure and injected on to the HPLC-MS. Concentrations were determined from the peak area by using the equation for linear regression obtained from the calibration curve. The

FIG. 2. A. Liquid chromatography-mass spectrometry (LCMS) trace of lovastatin (monacolin K) standard. The molecular ion is at m/z 427 = [M + Na]+ as reported.9 B. LCMS trace of lovastatin (monacolin K) hydroxy-acid standard. The molecular ion at m/z 421 = [M–H]− as reported.9 C. LCMS trace of simvastatin standard. The molecular ion is at m/z 441 = [M + Na]+ as reported.9
calibration curve was linear ($R^2 = 0.9954$ for lovastatin and 0.9927 forLovastatin hydroxy-acid, respectively) over the concentration range from 0.1 to 100 ng/mL. The lower level of quantitation (LOQ) established from the calibration curve by LCMS was 0.1 ng/mL based on 400 μL of plasma. Simvastatin was used as an internal standard as previously reported.$^9$

Statistical analysis

The pharmacokinetic parameters, peak plasma concentration ($C_{\text{max}}$), time to peak plasma concentration ($T_{\text{max}}$), and time for appearance of the drug in plasma were obtained by observation. The AUC from 0 to 24 hours after dosing was calculated by the linear trapezoidal rule. Elimination half-life ($t_{1/2}$) was estimated by $0.693/\lambda$, where $\lambda$ is the absolute value of the slope of a least-square linear regression of plasma drug concentration (in natural logarithm scale) over time at the terminal phase.

The pharmacokinetic parameters of lovastatin and Lovastatin hydroxy-acid were tabulated using mean ± SEM for taking Lovastatin and CRYR, respectively. This was a 2-by-2 crossover study with 7-day washout period. No carryover effect was identified, and no significant period and sequence effects were found; therefore, signed rank test was used to compare the pharmacokinetic parameters for Lovastatin versus CRYR.

All tests used were two sided with a significance level of 0.05. Statistical software SAS was used to carry out the analysis.

RESULTS

Characterization of the constituents of CRYR

This botanical dietary supplement consists mainly of rice, and by-products of fermentation. The main groups of constituents are shown in Table 1. Clearly the most abundant ingredient is starch, constituting over 73% of the bulk. The protein content is 6%. The other ingredients are found in much less quantity. Trace elements were analyzed by atomic absorption spectroscopy. Magnesium is the most abundant metal with 1094 μg/g of rice.

The typical HPLC trace for the monacolin mixture as found in CRYR is shown in Figure 1 and the Liquid Chromatography—Mass Spectrometry (LC-MS) traces of monacolin K, monacolin K hydroxy-acid, and simvastatin standards are shown in Figures 2A–C, respectively. Figure 3 shows the LC-MS trace of a plasma sample obtained from a human subject with simvastatin added as internal standard where monacolin K and monacolin K hydroxy-acid were detected. There is 1.23 mg of monacolin K in every capsule by assay of manufacture and 1.15 mg by HPLC analyses under the same conditions.

Pharmacokinetics

The mean values and pharmacokinetics for lovastatin and CRYR are summarized in Table 2 and the mean plasma concentration versus time profiles for monacolin K and monacolin K hydroxy-acid are shown in Figures 4A,B, respectively. Monacolin K was detected in plasma 30 minutes after ingestion of either Lovastatin or CRYR. The peak concentration reached at approximately 3 hours. The $C_{\text{max}}$ and AUC of Lovastatin was 22.42 ng/mL, and 80.47 higher than CRYR with $p$ value of 0.001 and 0.002, respectively. The dose-normalized $C_{\text{max}}$ and AUC of Lovastatin are 0.89 + 0.22 ng/mL, and 3.41 + 0.99 higher than CRYR with $p$ value of 0.001 and 0.002, respectively.

Monacolin K hydroxy-acid was detected 30 minutes after taking Lovastatin or CRYR but peaked at 4 hours, 1 hour later than when Monacolin K peaked. The $T_{\text{max}}$ for Lovastatin and CRYR hydroxys were similar ($p = 1.00$, signed rank test). The $C_{\text{max}}$ for Lovastatin hydroxy-acid is 36.63 ng/mL higher than the $C_{\text{max}}$ of CRYR hydroxys ($p = 0.001$, signed rank test). The AUC of Lovastatin hydroxy-acid is 258.5 larger than that of CRYR ($p = 0.001$). After normalization for dose, the AUC of Lovastatin is still 7.21 larger than that of CRYR ($p = 0.001$).

The individual sample for minor monacolins were not detectable by LC-MS/MS. However, the pooled plasma samples collected from three subjects showed the presence of minor monacolins reported to be present in CRYR.$^{10}$

FIG. 3. LCMS trace of human plasma sample showing monacolin K hydroxy-acid ($t_1 = 9.47$ min, base peak m/z 319.06 from molecular ion at m/z 421), Monacolin K ($t_1 = 12.47$ min, base peak m/z 325.24 from molecular ion at m/z 427), Simvastatin ($t_1 = 14.46$ min, base peak at m/z 325.12 from molecular ion at m/z 441.3) according to a previous report.$^9$
ples from all subjects were analyzed after pooled with two subjects. All the analysis showed the same pattern of minor monacolins. The data from one analysis are shown in Figures 5 and 6. Because of the unavailability of standards for these minor monacolins, Selected Ion Monitoring (SIM) was conducted in negative and positive ESI modes of CRYR, and then followed by MS-MS analyses of ions corresponding to each monacolin peak (Figs. 5 and 6). Peak identities were obtained by matching their molecular ions $(M-H)^-$ or $(M+Na)^+$ obtained by ES-MS/MS ions with expected values.10 Figure 5A shows the LCMS trace of the CRYR extract in negative mode with corresponding MS/MS ions for monacolin K hydroxy-acid ($t_R$ 11.38 min; $M-H$ m/z 421), dehydromonacolin K hydroxy-acid ($t_R$ 8.36 min; $M-H$ m/z 403), monacolin L hydroxy-acid ($t_R$ 9.49 min; $M-H$ m/z 321) and dihydromonacolin K hydroxy-acid ($t_R$ 14.10 min; $M-H$ m/z 423). Figure 5B shows the LCMS trace of the pooled human plasma sample with ions corresponding to monacolin L hydroxy-acid ($t_R$ 9.49 min; $M+Na$, m/z 423) and dihydromonacolin K hydroxy-acid ($t_R$ 14.09 min; $M-H$ m/z 423). Similarly, Figure 6A shows the LCMS trace of the CRYR extract in positive mode with corresponding MS/MS ions for monacolin K ($t_R$ 14.47 min; $M+Na$, m/z 427)+, dihydromonacolin K ($t_R$ 12.67 min; $M+Na$, m/z 429)+, monacolin L ($t_R$ 13.28 min; $M+Na$, m/z 327)+, and dehydromonacolin K ($t_R$ 18.90 min; $M+Na$, m/z 409). Figure 6B shows the LCMS trace of pooled plasma sample with ions corresponding to dehydromonacolin K ($t_R$ 18.82 min; $M+Na$, m/z 409).

**DISCUSSION**

In 1979, Endo11 reported that a strain of *Monascus* yeast naturally produces a substance that inhibits cholesterol synthesis, which he named monacolin K, as well as a family of eight monacolin-related substances with the ability to inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. In addition to the inhibitors of HMG-CoA reductase, red yeast rice has been found to contain sterols (β-sitosterol, campesterol, and stigmasterol), tannins, polyketide pigments, sapogenin, isoflavones and isoflavone glycosides, and monounsaturated fatty acids.11,12

CRYR has been shown to lower cholesterol in animals fed diets designed to induce hypercholesterolemia.13,14 In a double-blind placebo-controlled and diet-controlled study, CRYR was demonstrated to lower serum cholesterol by 23% in 40 hypercholesterolemic patients compared to 40 patients.
FIG. 5. A. Selected ion monitoring (SIM) spectra of the Chinese red yeast rice (CRYR) extract in negative mode with corresponding MS/MS ions for monacolin K hydroxy-acid (tR 11.38 min; M–H m/z 421), dehydromonacolin K hydroxy-acid (tR 8.36 min; M–H m/z 403), monacolin L hydroxy-acid (tR 9.49 min; M–H m/z 321), and dehydromonacolin K hydroxy-acid (tR 14.10 min; M–H m/z 423). B. SIM spectra of the pooled human plasma sample with corresponding MS/MS ions for monacolin L hydroxy-acid (tR 9.49 min; M–H m/z 321) and dehydromonacolin K hydroxy-acid (tR 14.09 min; M–H m/z 423).

FIG. 6. A. Selected ion monitoring (SIM) spectra of the Chinese red yeast rice (CRYR) extract in positive mode with corresponding MS/MS ions for monacolin K (tR 14.47 min; M + Na+, m/z 427), dehydromonacolin K (tR 17.26 min; M + Na+, m/z 429), monacolin L (tR 13.28 min; M + Na+, m/z 327), and dehydromonacolin K (tR 18.90 min; M + Na+, m/z 409). B. SIM spectra of pooled human plasma sample with ion corresponding to dehydromonacolin K (tR 18.82 min; M + Na+, m/z 409).
The benefits of statin drugs on the primary prevention of heart disease\(^{20,21}\) and in the secondary prevention of recurrent heart disease\(^{22,23}\) have been shown in several large, prospective clinical trials. These studies have increased interest in the prophylactic use of statins for heart disease prevention for individuals with hypercholesterolemia. The National Cholesterol Education Program (NCEP) guidelines were updated recently about pharmacologic intervention. NCEP is now advocating more aggressive therapy for patients with high and moderate risks.\(^{24}\) Although it is acknowledged that side-effects with statins are rare, there are data indicating that some statins may cause liver function abnormalities and, under certain circumstances, rhabdomyolysis in a dose-related fashion.\(^{25}\) Combined use of different statins in lower doses may decrease the incidence of side-effects.

### CONCLUSIONS

In summary this study demonstrated significantly lower serum monacolin K level for CRYR compared to equivalent cholesterol-lowering dose of lovastatin. CRYR may serve as a safe and effective natural alternative for people with modest elevation of cholesterol. The effect of red yeast rice on the cholesterol concentration is not caused by monacolin K alone but the combination of monacolin K and other monacolins, substances in the red yeast rice supplement.

### ACKNOWLEDGMENTS

Funding was supplied by the PHS/Institute of National Health IP50 AT 000151-01.

### REFERENCES

4. Havel RJ. Dietary supplement or drug? The case of cholestir.


Address reprint requests to:
Zhaoping Li, Ph.D., M.D.
Center for Human Nutrition
David Geffen School of Medicine
University of California, Los Angeles
900 Veteran Avenue, Room 12-217
Los Angeles, CA 90095-1742

E-mail: zli@mednet.ucla.edu